Ardelyx, Inc., is a clinical-stage biopharmaceutical company dedicated to the discovery, commercialization of innovative development, non-systematic small molecule drug therapy work, specializing in the gastrointestinal aspects, the treatment of heart and kidney, gastrointestinal and metabolic diseases. The company's developed drug discovery and design platform enables it to discover and design new drug candidates in a fast and cost-effective way. Founded in Delaware on October 17, 2007, the company changed its name from nteryx to ardelyx in June 2008. 

Expected P&L on Expiry

Key Stats

Pricing Model

About ARDX20260220C8